Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Camrelizumab, and Apatinib in Advanced Esophageal Cancer
NCT06745193Phase 2Not yet recruiting
- Sponsor
- Peking University
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06745193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745193.